Investor Presentation is attached herewith

348/LG/SE/NOV/2026/GBSL November 14, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presentation Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation on Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. Kindly take the same on record. Thanking You, Yours truly, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No. A39579 Encl.: As above INVESTOR PRESENTATION Delivering Care & Cure Q2 FY2027 Gufic Biosciences Limited IMPORTANT NOTICE Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosciences Certain statements contained in this presentation that are not statements of historical fact Limited (the “Company”). By accessing this presentation, you are agreeing to be bound by constitute “forward-looking statements.” You can generally identify forward looking the trailing restrictions. statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “objective”, “goal”, “plan”, “potential”, “project”, This presentation does not constitute or form part of any offer or invitation or inducement “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import. to sell or issue, or any solicitation of any offer or recommendation to purchase or These forward-looking statements involve known and unknown risks, uncertainties, subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its assumptions and other factors that may cause the Company’s actual results, performance distribution form the basis of, or be relied on in connection with, any contract or or achievements to be materially different from any future results, performance or commitment thereof. In particular, this presentation is not intended to be a prospectus or achievements expressed or implied by such forward-looking statements or other offer document under the applicable laws of any jurisdiction, including India. No projections. Important factors that could cause actual results, performance or representation or warranty, express or implied, is made as to, and no reliance should be achievements to differ materially include, among others: (a) our ability to successfully placed on, the fairness, accuracy, completeness or correctness of the information or implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory opinions contained in this presentation. Such information and opinions are in all events norms applicable to the Company, (d) technological changes, (e) investment income, (f) not current after the date of this presentation. There is no obligation to update, modify or cash flow projections, and (g) other risks. amend this communication or to otherwise notify the recipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes This presentation is for general information purposes only, without regard to any specific inaccurate. objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. Gufic Biosciences Limited | Investor Presentation Q2 FY2027 2 Q2 FY27 Business & Financial Highlights • Indore facility: the manufacturing platform • Hospital injectable platform • Women's health platform • Botulinum toxin platform • Nutra, Ayurveda & others • International business and Indore scale-up • Research & development • Financials Q2 FY27 BUSINESS UPDATE Q2 FY27 at a glance: direction across the business 1 Indore manufacturing platform 2 Hospital injectable platform 3 Women's health platform The US FDA inspection brings the regulated- Formulary depth ahead of portfolio breadth, In fertility, evidence and depth of clinic wallet market timeline forward. Scale-up stays own-manufactured brands and differentiated share rather than centre count; in Zenova, a deliberately paced; the operating leverage sits delivery formats as the point of difference, and prescription-led portfolio in which power brands behind closing the observations and the new account-acquisition models on a clean and several growth engines now carry the certifications in progress. receivable base. division. 4 Botulinum toxin platform 5 Nutra, Ayurveda & others 6 International business Aesthetics moves from a single toxin brand A science-led chronic care platform built on a Registrations this quarter converted directly into towards a full portfolio as fillers arrives, backed leading herbal franchise —the core holding first orders in the Gulf and Latin America, while by Indian clinical evidence; therapeutics leadership, newer pillars gaining weight, and the the European footprint widened through Gufic continues to compound quietly on protocol- allopathic pain adjacency now commercial. Ireland and partners —approvals now mandated demand. translating into supply rather than sitting on file. Gufic Biosciences Limited | Investor Presentation Q2 FY2027 4 Q2 FY27 BUSINESS UPDATE | MANUFACTURING Indore facility: the manufacturing platform We have built one of the most advanced lyophilized Q2 FY27 PROGRESS injectable facilities, commenced production in October Regulated-market readiness 2024 Q2 work moved from capability extension to regulated-market readiness. The site is now registered with the US FDA, a first product dossier was filed from it, DESIGNED TO GLOBAL REGULATORY STANDARDS and audits by prospective partners for the US and UK markets were hosted. WHO GMP EU GMP ANVISA MHRA USFDA INSTALLED CAPACITY Capability extension The depot suite is ready for trials and media fills ahead of domestic commercial 50 mn 30 mn 72 mn batches. The spray-dried route for a lipid-based antifungal is on the verge of completion, and an injectable emulsion format moved through scale-up, with Lyophilized vials per Liquid vials per year Ampoules per year exhibit batches planned in Q3. year Commercial production commenced in October 2024. The US FDA inspection brings the regulated-market timeline forward. Scale-up stays deliberately paced; the operating leverage sits behind closing the observations DIRECTION and the certifications in progress. Gufic Biosciences Limited | Investor Presentation Q2 FY2027 5 Q2 FY27 BUSINESS UPDATE | MANUFACTURING Indore facility: timeline of our phased approach Milestone Target Status Commentary Installation & Operational Qualification Completed –facility meets WHO GMP, EU GMP, ANVISA, MHRA, USFDA design October 2023 ●Completed (IQ/OQ) standards Performance Qualification (PQ) All Lines & Dec 2023 –Jun 2024 ●Completed Completed with multiple container trials; parameters locked Utilities Media Fills (Aseptic Process Simulations) Jul 2024 –Oct 2024 ●Completed Completed for all four lines; sterility validated Product Permissions from State FDA Ongoing ●In progress 203 approvals received to date; more in pipeline Tech Transfer for existing products from Completed for 40 products; stability studies in progress. 27 more products under Navsari & Process Validation Batches for Oct 2024 –ongoing ●In progress development initial products Vendor Audits Indian Pharma Majors H1-FY26 ●In progress 20+ completed, more lined up; CMO contracts commenced 30% Capacity Utilization FY26 ●In progress On-track Global Regulatory Clearance EU GMP & UK MHRA FY27 ●In progress EU audit completed; compliance report submitted; certification awaited Pre-approval inspection completed; three o [Showing first 8,000 characters — download PDF for full document]